In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program.
[[{"type":"media","view_mode":"media_crop","fid":"11554","attributes":{"alt":"Stephen Rose","class":"media-image media-image-left","id":"media_crop_8501769795264","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"218","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]In February 2011, the FDA approved the first X-ray mammography system that provides 3-D images for breast cancer screening and diagnosis, Hologic’s Selenia Dimensions. The 3-D tomosynthesis is being offered in fewer than two dozen locations in the U.S., and among them is Houston Breast Imaging in Texas.
In this podcast, Stephen Rose, MD, president and CEO of Houston Breast Imaging and a principal investigator of the 3-D tomosynthesis clinical trials in 2010, discusses the benefits of the new technology and what his practice learned when implementing the screening program. .
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.